Table 2.
Limbic and neocortical AChE hydrolysis rates (k3; min−1) and striatal VMAT2 binding potential (BPND) in the Parkinson’s disease and control subjects
| Parkinson’s disease (n = 58) | Controls (n = 26) | Statistical significance | |
|---|---|---|---|
| Neocortical AChE k3 | 0.0272 ±0.0026 | 0.0303 ± 0.0035 | t = 4.6; P < 0.0001 |
| Hippocampal AChE k3 | 0.0426 ± 0.0058 | 0.0472 ± 0.0091 | tapprox = 2.3; P = 0.025 |
| Amygdala AChE k3 | 0.0596 ± 0.0096 | 0.0681 ± 0.0156 | tapprox = 2.5; P = 0.015 |
| Striatal VMAT2 BPND | 0.96 ± 0.32 | 1.98 ± 0.32 | t = 13.4; P < 0.0001 |
Data are mean (±SD).